Liver Disease Clinical Trials

Showing 101-120 of 690 trials

Lifestyle Guidance Methods in NAFLD

NCT05792488

To determine the efficiency of lifestyle modification (due to a dietitian or digital application) compared to standard of care.

Non-Alcoholic Fatty Liver Disease

Ziekenhuis Oost-Limburg300 participantsStarted Oct 2022

Genk, Limburg, Belgium

ACTIVE_NOT_RECRUITING

Frequency of Portal Hypertension Among Patient With Cirrhotic Liver With Ultrasound

NCT07051369

Portal hypertension is a common and serious complication of liver cirrhosis, often leading to life-threatening conditions such as variceal bleeding, ascites, and hepatic encephalopathy.

Cirrhosis, Liver

Superior University150 participantsStarted Mar 2025

Rahim Yar Khan, Punjab Province, Pakistan

NOT_YET_RECRUITINGPHASE1/PHASE2

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

NCT07042919

This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Zanzalintinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Giving zanzalintinib may be safe, tolerable, and/or effective in treating patients with advanced liver cancer.

Advanced Hepatocellular CarcinomaCirrhosisStage III Hepatocellular Carcinoma AJCC v8+1 more

Northwestern University53 participantsStarted Mar 2026

Chicago, Illinois, United States

Lifestyle Guidance Methods in NAFLD

Frequency of Portal Hypertension Among Patient With Cirrhotic Liver With Ultrasound

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

Related Searches

Accuracy of Imaging Techniques in Diagnosing Steatohepatitis and Fibrosis in NAFLD Patients

RESTORE Declined Livers Study

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

Liver Health and Metabolic Function in People With Obesity

Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients

Endosonographic Shear Wave Elastography to Assess Liver and Splenic Fibrosis

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients

FMT in Cirrhosis and Hepatic Encephalopathy

Randomised Prospective Study of CUSA Versus Radiofrequency Ablation Technique in Liver Resections

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial